What type of study is this?

This is a Human Clinical Trial study.

September 17, 2025Proceedings on CD-ROM - International Society for Magnetic Resonance in Medicine. Scientific Meeting and Exhibition/Proceedings of the International Society for Magnetic Resonance in Medicine, Scientific Meeting and Exhibition0 citations

Rationale and Clinical Feasibility of MRI-Guided Percutaneous Transgluteal Route In-Bore Prostate Biopsy at 0.55T

View Full Paper

TKTejinder Kaur YJYun Jiang NSNicole Seiberlich

Key Points

The percutaneous transgluteal MRI-guided prostate biopsy achieved a cancer detection rate of 77%, confirming its effectiveness.
Among the lesions biopsied, 80% had positive cores, demonstrating the method's capacity for accurate cancer diagnosis.
Seventy percent of participants experienced changes in management, highlighting the approach's clinical relevance.
Conducted under moderate sedation, this feasible method aligns with the skills of existing CT interventionalists.

Abstract

Motivation: MR-guided in-bore prostate biopsy is typically performed at 1.5 or 3T via transrectal or percutaneous transperineal approaches. Feasibility of performance at lower field and using a percutaneous transgluteal approach is uncertain. Goal(s): The feasibility of a percutaneous transgluteal approach for in-bore MRI-guided prostate biopsies was explored. Approach: With IRB approval, 13 participants were biopsied at 0.55T under moderate sedation. Results: 10/13 participants (77% cancer detection rate) and 12/15 lesions (80%) had positive cores. 70% of cases affected management. Impact: Percutaneous transgluteal in-bore MRI-guided prostate biopsy is effective and offers an anesthesia-sparing option aligning with existing skills of CT interventionalists.

Ask AI

Helpful

Bookmark

View Full Paper

Ask AI

Helpful

Bookmark

View Full Paper

Rationale and Clinical Feasibility of MRI-Guided Percutaneous Transgluteal Route In-Bore Prostate Biopsy at 0.55T

Key Points

Abstract

Cite This Study